Comparison of topical acyclovir and penciclovir in recurrent herpes labialis treatment
Öz
Purpose: The aim of this study is to compare the effects of acyclovir and penciclovir creams in the treatment of recurrent herpes labialis.
Materials and Methods: Seventy patients with pre-diagnosed recurrent herpes labialis lesions were enrolled in this study. Diagnosis was confirmed with HSV-1 IgM antibody test. Patients were separated under 2 treatment groups as acyclovir and penciclovir cream. Both agents were applied until complete healing of the lesions was seen. Burning, itching and bleeding scores; time of erythema, vesicles, ulceration, crusting and crust loss of the lesions were recorded. Pain values of the patients were recorded using a visual analog scale (VAS) and DASS-21 scale was used to measure emotional state related to depression, anxiety and stress.
Results: Pain level in the acyclovir group was significantly lower than the penciclovir group in the 3rd day, though with no difference in the following days. DASS-21 scores revealed signs of depression on 62.8% of the patients, anxiety on 34.2% of the patients, and stress on 41.4% of the patients in moderate or higher levels. While the pain level was higher in patients with high anxiety severity, it was observed that the pain level was low in patients with high stress intensity.
Conclusion: Although it is not possible to cure recurrent herpes labialis completely, any methods and drugs that shorten the healing time of the lesion and reduce pain and discomfort gains importance. Our study showed that acyclovir is superior in reducing pain.
Anahtar Kelimeler
Herpes Simplex Virus, Recurrent Herpes Labialis, Acyclovir
Destekleyen Kurum
This work was supported by the Gaziantep University Scientific Research Projects Coordination Unit
Proje Numarası
DHF.UT.19.01
Kaynakça
- 1. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26(3):541–53.
- 2. Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One. 2015;10(10):e0140765.
- 3. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513–8.
- 4. Andrews C, Camichael E. A Note on the Presence of Antibodies to Herpes Virus. In Post-Encephalitic and Other Human Sera. Lancet. 1930;215(5564):857–8.
- 5. Honarmand M, Farhadmollashahi L, Vosoughirahbari E. Comparing the effect of diode laser against acyclovir cream for the treatment of herpes labialis. J Clin Exp Dent. 2017;9(6):e729–32.
- 6. Chen F, Xu H, Liu J, Cui Y, Luo X, Zhou Y, et al. Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta-analysis. J Oral Pathol Med. 2017;46(8):561–8.
- 7. Vere Hodge RA, Field HJ. Antiviral agents for herpes simplex virus. Adv Pharmacol. 2013;67:1–38.
- 8. Emmert DH. Treatment of common cutaneous herpes simplex virus infections. Am Fam Physician. 2000;61(6):1697–704.
- 9. Aronson JK, editor. Aciclovir. Meyler’s Side Effects of Drugs. Elsevier B.V.; 2016. 53–57 p.
- 10. Femiano F, Gombos F, Scully C. Recurrent herpes labialis: Efficacy of topical therapy with penciclovir compared with acyclovir (aciclovir). Oral Dis. 2001;7(1):31–3.
